Latest Eversept Partners, LP Stock Portfolio
Eversept Partners, LP Performance:
2024 Q4: -3.78%YTD: 28.08%2023: 3.59%
Performance for 2024 Q4 is -3.78%, and YTD is 28.08%, and 2023 is 3.59%.
About Eversept Partners, LP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Eversept Partners, LP reported an equity portfolio of $1.1 Billions as of 31 Dec, 2024.
The top stock holdings of Eversept Partners, LP are NTRA, , VERA. The fund has invested 12.3% of it's portfolio in NATERA INC and 11% of portfolio in GSK PLC.
The fund managers got completely rid off INSMED INC (INSM), BAUSCH HEALTH COS INC (BHC) and INTRA-CELLULAR THERAPIES INC (ITCI) stocks. They significantly reduced their stock positions in SYNDAX PHARMACEUTICALS INC (SNDX), AUTOLUS THERAPEUTICS PLC (AUTL) and ARCUTIS BIOTHERAPEUTICS INC (ARQT). Eversept Partners, LP opened new stock positions in BRUKER CORP (BRKR), EDWARDS LIFESCIENCES CORP (EW) and DEXCOM INC (DXCM). The fund showed a lot of confidence in some stocks as they added substantially to LIQUIDIA CORPORATION (LQDA), BIOCRYST PHARMACEUTICALS INC (BCRX) and PROTAGONIST THERAPEUTICS INC (PTGX).
The top stock holdings of Eversept Partners, LP are NTRA, , VERA. The fund has invested 12.3% of it's portfolio in NATERA INC and 11% of portfolio in GSK PLC.
The fund managers got completely rid off INSMED INC (INSM), BAUSCH HEALTH COS INC (BHC) and INTRA-CELLULAR THERAPIES INC (ITCI) stocks. They significantly reduced their stock positions in SYNDAX PHARMACEUTICALS INC (SNDX), AUTOLUS THERAPEUTICS PLC (AUTL) and ARCUTIS BIOTHERAPEUTICS INC (ARQT). Eversept Partners, LP opened new stock positions in BRUKER CORP (BRKR), EDWARDS LIFESCIENCES CORP (EW) and DEXCOM INC (DXCM). The fund showed a lot of confidence in some stocks as they added substantially to LIQUIDIA CORPORATION (LQDA), BIOCRYST PHARMACEUTICALS INC (BCRX) and PROTAGONIST THERAPEUTICS INC (PTGX).
Eversept Partners, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Eversept Partners, LP made a return of -3.78% in the last quarter. In trailing 12 months, it's portfolio return was 28.08%.
New Buys
| Ticker | $ Bought |
|---|---|
| bruker corp | 13,771,800 |
| edwards lifesciences corp | 12,635,300 |
| dexcom inc | 11,563,500 |
| teleflex incorporated | 10,987,800 |
| vaxcyte inc | 10,444,400 |
| guardant health inc | 8,432,900 |
| astrazeneca plc | 6,726,350 |
| medpace hldgs inc | 6,328,650 |
New stocks bought by Eversept Partners, LP
Additions
| Ticker | % Inc. |
|---|---|
| liquidia corporation | 314 |
| biocryst pharmaceuticals inc | 269 |
| protagonist therapeutics inc | 52.47 |
| elevance health inc | 49.9 |
| icon plc | 40.85 |
| centene corp del | 39.67 |
| hca healthcare inc | 36.2 |
| celldex therapeutics inc new | 27.43 |
Additions to existing portfolio by Eversept Partners, LP
Reductions
| Ticker | % Reduced |
|---|---|
| syndax pharmaceuticals inc | -91.64 |
| autolus therapeutics plc | -75.68 |
| arcutis biotherapeutics inc | -72.43 |
| inflarx nv | -69.64 |
| community health sys inc new | -67.79 |
| repligen corp | -66.95 |
| united therapeutics corp del | -66.63 |
| karyopharm therapeutics inc | -62.35 |
Eversept Partners, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| bausch health cos inc | -12,492,300 |
| insmed inc | -79,526,500 |
| brookdale sr living inc | -5,848,010 |
| paragon 28 inc | -5,004,740 |
| aerovate therapeutics inc | -1,013,940 |
| maravai lifesciences hldgs i | -2,800,190 |
| nevro corp | -1,754,030 |
| kura oncology inc | -3,759,460 |
Eversept Partners, LP got rid off the above stocks
Sector Distribution
Eversept Partners, LP has about 80.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 80.2 |
| Others | 19.5 |
Market Cap. Distribution
Eversept Partners, LP has about 38.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| LARGE-CAP | 38.7 |
| MID-CAP | 28.2 |
| UNALLOCATED | 20.5 |
| SMALL-CAP | 11 |
| MICRO-CAP | 1.7 |
Stocks belong to which Index?
About 46.7% of the stocks held by Eversept Partners, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 53.3 |
| RUSSELL 2000 | 29.5 |
| S&P 500 | 17.2 |
Eversept Partners, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Eversept Partners, LP
Eversept Partners, LP has 62 stocks in it's portfolio. About 55.3% of the portfolio is in top 10 stocks. CYH proved to be the most loss making stock for the portfolio. NTRA was the most profitable stock for Eversept Partners, LP last quarter.
Last Reported on: 14 Feb, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABSI | absci corporation | 0.05 | 199,464 | 522,596 | reduced | -26.9 | ||
| ALEC | alector inc | 0.03 | 200,095 | 378,180 | reduced | -39.87 | ||
| AMRN | amarin corp plc | 0.06 | 1,516,590 | 735,547 | reduced | -54.17 | ||
| ARQT | arcutis biotherapeutics inc | 0.24 | 191,158 | 2,662,830 | reduced | -72.43 | ||
| AUTL | autolus therapeutics plc | 0.02 | 98,895 | 232,403 | reduced | -75.68 | ||
| AVTE | aerovate therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTR | avantor inc | 0.32 | 168,369 | 3,547,540 | unchanged | 0.00 | ||
| BCRX | biocryst pharmaceuticals inc | 1.32 | 1,980,310 | 14,891,900 | added | 269 | ||
| BHC | bausch health cos inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BKD | brookdale sr living inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BRKR | bruker corp | 1.22 | 234,934 | 13,771,800 | new | |||
| CLDX | celldex therapeutics inc new | 1.61 | 719,836 | 18,190,300 | added | 27.43 | ||
| CNC | centene corp del | 1.01 | 188,493 | 11,418,900 | added | 39.67 | ||
| CYH | community health sys inc new | 0.75 | 2,827,000 | 8,452,730 | reduced | -67.79 | ||
| DHR | danaher corporation | 0.45 | 22,209 | 5,098,080 | reduced | -42.21 | ||
| DXCM | dexcom inc | 1.03 | 148,688 | 11,563,500 | new | |||
| ELV | elevance health inc | 0.96 | 29,178 | 10,763,800 | added | 49.9 | ||
| EOLS | evolus inc | 0.38 | 383,045 | 4,228,820 | reduced | -15.45 | ||
| EW | edwards lifesciences corp | 1.12 | 170,678 | 12,635,300 | new | |||
| FNA | paragon 28 inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||